Practical Advice for Management of Chronic GVHD
February 29th 2024The panel provides advice for community providers treating patients with chronic GVHD, stressing effective communication, staying updated on evolving drugs, and collaborating with specialized multidisciplinary groups for optimal patient care.
Read More
Quality of Life and Patient Reported Outcomes (PRO) in Chronic GVHD
February 29th 2024The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.
Read More
Future Landscape of Chronic GVHD
February 22nd 2024Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz share their predictions for the next 3 to 5 years in chronic GVHD management. The panel anticipates advancements in earlier treatment, potential elimination of frontline corticosteroids, and a shift towards preventive strategies and personalized medicine.
Read More
Emerging Agents in GVHD: Axatilimab
February 22nd 2024The panel reviews axatilimab, an emerging agent for chronic GVHD under clinical studies. The experts explore findings from the Agave-201 study, highlighting potential challenges of intravenous administration and axatilimab’s unique mechanisms.
Read More
Third Line Treatment in Chronic GVHD
February 15th 2024Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss a complex chronic GVHD case post-allogeneic transplant. The panel explores third-line options, including belumosudil, ibrutinib, photopheresis, and clinical trials, emphasizing shared decision-making and the need for well-designed trials in guiding treatment decisions.
Read More
Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss the approval and real-world experiences of ibrutinib and ruxolitinib for chronic GVHD. The panel discusses the challenges and varying effectiveness observed in real-world usage, contrasting the experiences of the two drugs.
Read More
Phases of Pathophysiology of Chronic GVHD
January 11th 2024The expert panel explores the immunological aspects of chronic GVHD, highlighting challenges in simultaneous management, addressing fibrosis, and emphasizing the importance of early intervention in evolving transplant care practices.
Read More
Acute Versus Chronic Graft-Versus-Host Disease (GVHD)
January 11th 2024Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz distinguish acute from chronic graft-versus-host disease (GVHD), how such distinction has changed over the last decades, and provide an overview of consensus definitions for disease grading.
Read More
Indications for Allogeneic Stem Cell Transplantation in the Treatment of Hematological Malignancies
March 23rd 2023Sophie Paczesny, MD, PhD, explains which malignancies allogeneic transplantation can be used as a potentially curative treatment approach, and which patients are best suited for transplant.
Read More